Case Report
Characteristics and Treatment Results of 5 Patients with Fibrous Dysplasia and Review of the Literature
Table 1
Bone markers before and after bisphosphonate treatment.
| | Patient 1 (PFD) | ALP (U/L) | Ca (mg/dL) | P (mg/dL) | PTH (pg/mL) | OC (ng/mL) | DPD (nmol/L) | Dvit (nmol/L) |
| | Before tx | 975 | 9.6 | 3.4 | 81 | 50.7 | 83.1 | 56 | | After 6 months of 1st pamidronate tx | 612 | 9.3 | 3.4 | 66 | 100 | 65.6 | — | | After 6 months of 2nd pamidronate tx | 632 | 9.7 | 2.8 | 55 | 93.7 | 41.7 | — | | After 2 years | 520 | 9.2 | NA | 64.98 | 92.9 | 38.55 | — |
| | Patient 2 (MFD) | ALP (U/L) | Ca (mg/dL) | P (mg/dL) | PTH (pg/mL) | OC (ng/mL) | DPD (nmol/L) | Dvit (nmol/L) |
| | Before tx | 54 | 10.5 | 4 | 20 | 10.8 | 5.45 | 24 | | After 12 months of 1st pamidronate tx | 55 | 10 | 3.2 | 29 | 5.4 | 4.6 | — |
| | Patient 3 (MFD) | ALP (U/L) | Ca (mg/dL) | P (mg/dL) | PTH (pg/mL) | OC (ng/mL) | DPD (nmol) | Dvit (nmol/L) |
| | Before tx | 66 | 9.6 | 4.7 | 31 | 5.56 | 10.97 | 40 | | After 12 months of 1st zoledronic a. tx | 84 | 10.1 | 4.3 | 37.6 | 3.97 | 8 | — |
| | Patient 4 (MFD) | ALP (U/L) | Ca (mg/dL) | P (mg/dL) | PTH (pg/mL) | OC (ng/mL) | DPD (nmol/L) | Dvit (nmol/L) |
| | Before tx | 111 | 9.6 | 3.2 | 32.7 | 25.6 | 11.43 | 31 | | After 12 months of 1st pamidronate tx | 84 | 9.3 | 3.2 | 31.9 | 12.6 | 11.01 | — |
| Patient 5 (PFD)
(MAS) | ALP (U/L) | Ca (mg/dL) | P (mg/dL) | PTH (pg/mL) | OC (ng/mL) | DPD (nmol/L) | Dvit (nmol/L) |
| | Before tx | 227 | 10.5 | 3.9 | 54.5 | 15.8 | 8 | 29 | | After 3 months of 1st pamidronate tx | 138 | 9.5 | 3.0 | 48 | NA | 5.2 | — |
|
|
